Inflammatory Bowel Diseases最新文献

Incidence of Osteoporosis and Osteopenia in Newly Diagnosed Inflammatory Bowel Disease: A Population-Based Cohort Study.

IF 4.5 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-04-08 DOI: 10.1093/ibd/izaf063

Mohamed Attauabi, Gorm Roager Madsen, Jakob Præst Holm, Flemming Bendtsen, Søren Møller, Jakob Benedict Seidelin, Johan Burisch

{"title":"Incidence of Osteoporosis and Osteopenia in Newly Diagnosed Inflammatory Bowel Disease: A Population-Based Cohort Study.","authors":"Mohamed Attauabi, Gorm Roager Madsen, Jakob Præst Holm, Flemming Bendtsen, Søren Møller, Jakob Benedict Seidelin, Johan Burisch","doi":"10.1093/ibd/izaf063","DOIUrl":"https://doi.org/10.1093/ibd/izaf063","url":null,"abstract":"Background: Individuals with Crohn's disease (CD) and ulcerative colitis (UC) are at risk of developing osteoporosis. In Denmark, osteoporosis has been observed in 12.0% of postmenopausal women and 2.6% in men aged ≥ 50 years in the general population. We aimed to conduct a population-based analysis determining bone mineral density (BMD) at diagnosis of UC and CD.Methods: All adult patients diagnosed with UC or CD between May 2021 and May 2023 in an area covering 20% (1.2 million inhabitants) of the Danish population were invited for dual-energy X-ray absorptiometry at inflammatory bowel disease (IBD) diagnosis.Results: In total, 209 and 141 patients with UC and CD, respectively, were included. Among postmenopausal women (age ≥ 52 years) with UC, 15/42 (35.7%) had osteoporosis and 17/42 (40.5%) had osteopenia, while rates among patients with CD were 6/21 (28.6%, P = .57) and 8/21 (38.1%, P = .86), respectively. Among males aged ≥ 50 years, the rates were 5/38 (13.2%) and 17/38 (44.7%) in UC, respectively, and 3/24 (12.5%, P = 1.00) and 12/24 (50.0%, P = .69) in CD, respectively. Among younger patients, BMD below the expected range for age was observed in 3/69 (4.3%) and 3/60 (5.0%) of females and males with UC, and in 1/42 (2.4%) and 8/54 (14.8%) with CD, respectively. No nutritional or inflammatory marker, including C-reactive protein, fecal calprotectin, Mayo Endoscopic Score, or Simple Endoscopic Score for CD correlated with the T-score.Conclusions: This population-based study demonstrated high rates of osteoporosis among postmenopausal women and males aged ≥ 50 years at IBD diagnosis, highlighting the need for systematic evaluation in these patients.","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143803151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Letter: Predictors of Complicated Disease Course in Children and Adults With Ulcerative Colitis-Authors' Reply.

IF 4.5 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-04-08 DOI: 10.1093/ibd/izaf071

Ohad Atia, Dan Turner

引用次数: 0

Health Outcomes, Discrimination, and Stigma Among Sexual and Gender Minority People With Inflammatory Bowel Disease.

IF 4.5 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-04-08 DOI: 10.1093/ibd/izaf054

Kira L Newman, Patricia A Wren, Millie D Long, Peter D R Higgins

{"title":"Health Outcomes, Discrimination, and Stigma Among Sexual and Gender Minority People With Inflammatory Bowel Disease.","authors":"Kira L Newman, Patricia A Wren, Millie D Long, Peter D R Higgins","doi":"10.1093/ibd/izaf054","DOIUrl":"https://doi.org/10.1093/ibd/izaf054","url":null,"abstract":"Background: Sexual and gender minority (SGM) individuals often experience more discrimination and worse health than non-SGM people. Less is known about SGM individuals with inflammatory bowel disease (IBD). We studied IBD outcomes, discrimination, illness-related stigma, and SGM status in a cross-sectional survey.Methods: In total, 1586 IBD Partners e-cohort participants self-reported sexual orientation, gender identity, and prior IBD treatment. They completed the Short Crohn's Disease Activity Index or Simple Clinical Colitis Activity Index, the Everyday Discrimination Scale, and the Paradox of Self Stigma (PASS-24) scale. We performed regression analyses controlling for age, race, disease duration, and IBD type.Results: SGM people were 7.8% (n = 124) of the cohort. SGM participants were younger than non-SGM participants (median age 40 vs. 54 years, P < .001). Among SGM individuals, 67% (n = 74) were in remission based on disease activity scores. Among non-SGM individuals, 74% (n = 936) were in remission (P = .097). Similar proportions of SGM and non-SGM persons reported prior IBD-related hospitalization (40% vs. 37%, P = .426; adjusted odds ratio [aOR] 0.95, 95% confidence interval [CI], 0.62-1.45) and IBD-related surgery (52% vs. 54%, P = .707, aOR 1.25, 95% CI, 0.81-1.94). SGM respondents reported more discrimination (71% vs. 47%, P < .001), and 43% of SGM individuals reported healthcare-related discrimination versus 21% of non-SGM individuals (P < .001). SGM persons also endorsed more internalized stigma (median PASS-24 scores 53 vs. 47, P = .026).Conclusions: SGM individuals with IBD are more likely to experience discrimination, including in healthcare, and illness-related stigma. These may significantly impact the quality of life and should be considered in the care of SGM people with IBD.","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143803148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy of Mirikizumab in Patients with Prior Ustekinumab Exposure: A Case Series.

IF 4.5 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-04-08 DOI: 10.1093/ibd/izaf018

Tsunaki Sawada, Masanao Nakamura, Takeshi Yamamura, Keiko Maeda, Eri Ishikawa, Kentaro Murate, Hiroki Kawashima

引用次数: 0

Assessment and Impact of Age on the Safety and Efficacy of Etrasimod in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From the ELEVATE UC Clinical Program.

IF 4.5 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-04-04 DOI: 10.1093/ibd/izae308

Gary R Lichtenstein, Jessica R Allegretti, Edward V Loftus, Peter M Irving, Rupa Banerjee, Aline Charabaty, Tanja Kuehbacher, Eustratios Bananis, John C Woolcott, Alexis B Dalam, Krisztina Lazin, Michael Keating, Aoibhinn McDonnell, Silvio Danese

{"title":"Assessment and Impact of Age on the Safety and Efficacy of Etrasimod in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From the ELEVATE UC Clinical Program.","authors":"Gary R Lichtenstein, Jessica R Allegretti, Edward V Loftus, Peter M Irving, Rupa Banerjee, Aline Charabaty, Tanja Kuehbacher, Eustratios Bananis, John C Woolcott, Alexis B Dalam, Krisztina Lazin, Michael Keating, Aoibhinn McDonnell, Silvio Danese","doi":"10.1093/ibd/izae308","DOIUrl":"https://doi.org/10.1093/ibd/izae308","url":null,"abstract":"Background: Patient age can impact the safety and efficacy of ulcerative colitis (UC) treatments. Etrasimod is an oral, once daily (QD), selective sphingosine 1-phosphate1,4,5 receptor modulator for the treatment of moderately to severely active UC. Here, we evaluate the impact of age on etrasimod safety and efficacy in patients with UC in the phase 3 ELEVATE UC clinical program.Methods: Data were pooled from ELEVATE UC 52 and ELEVATE UC 12 in patients receiving etrasimod 2 mg QD or placebo. Proportions and incidence rates (IRs) per 100 patient-years of treatment-emergent adverse events (AEs) were stratified by age (<40, 40-59, and ≥60 years). With the same age stratifications, efficacy was evaluated in patients with baseline Modified Mayo scores of 5-9 and 4-9 for the primary efficacy endpoint (clinical remission) and secondary efficacy endpoints.Results: Overall, 787 patients were enrolled (<40 years, n = 420 [53.4%]; 40-59 years, n = 276 [35.1%]; and ≥60 years, n = 91 [11.6%]). Arthralgia, fatigue, and hypertension IRs were higher in older patients, irrespective of treatment. Serious AEs and AEs leading to treatment discontinuation were low and consistent across age groups. Significantly more patients receiving etrasimod 2 mg QD vs placebo achieved efficacy endpoints, regardless of age.Conclusions: The safety profile of etrasimod 2 mg QD in the ELEVATE UC population was consistent across age groups, with no change in the incidence of AEs. Patients receiving etrasimod vs placebo showed significant clinical benefit, regardless of age.Clinicaltrials.gov: NCT03945188; NCT03996369.","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143780049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Artificial Intelligence for Classification of Endoscopic Severity of Inflammatory Bowel Disease: A Systematic Review and Critical Appraisal.

IF 4.5 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-03-31 DOI: 10.1093/ibd/izaf050

Michelle Chae Min Lee, Armin Farahvash, Petros Zezos

{"title":"Artificial Intelligence for Classification of Endoscopic Severity of Inflammatory Bowel Disease: A Systematic Review and Critical Appraisal.","authors":"Michelle Chae Min Lee, Armin Farahvash, Petros Zezos","doi":"10.1093/ibd/izaf050","DOIUrl":"https://doi.org/10.1093/ibd/izaf050","url":null,"abstract":"Background: Endoscopic scoring indices for ulcerative colitis and Crohn's disease are subject to inter-endoscopist variability. There is increasing interest in the development of deep learning models to standardize endoscopic assessment of intestinal diseases. Here, we summarize and critically appraise the literature on artificial intelligence-assisted endoscopic characterization of inflammatory bowel disease severity.Methods: A systematic search of Ovid MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and IEEE Xplore was performed to identify reports of AI systems used for endoscopic severity classification of IBD. Selected studies were critically appraised for methodological and reporting quality using APPRAISE-AI.Results: Thirty-one studies published between 2019 and 2024 were included. Of 31 studies, 28 studies examined endoscopic classification of ulcerative colitis and 3 examined Crohn's disease. Researchers sought to accomplish a wide range of classification tasks, including binary and multilevel classification, based on still images or full-length colonoscopy videos. Overall scores for study quality ranged from 41 (moderate quality) to 64 (high quality) out of 100, with 28 out of 31 studies within the moderate quality range. The highest-scoring domains were clinical relevance and reporting quality, while the lowest-scoring domains were robustness of results and reproducibility.Conclusions: Multiple AI models have demonstrated the potential for clinical translation for ulcerative colitis. Research concerning the endoscopic severity assessment of Crohn's disease is limited and should be further explored. More rigorous external validation of AI models and increased transparency of data and codes are needed to improve the quality of AI studies.","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Impact of Endoscopic Healing on Disease-Related Outcomes in Patients With Ulcerative Proctitis.

IF 4.5 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-03-31 DOI: 10.1093/ibd/izaf044

Esther Y Liu, Anjile An, Shaira Khan, Robert Battat, Randy Longman, Ellen Scherl, Laura Sahyoun, Dana J Lukin

{"title":"The Impact of Endoscopic Healing on Disease-Related Outcomes in Patients With Ulcerative Proctitis.","authors":"Esther Y Liu, Anjile An, Shaira Khan, Robert Battat, Randy Longman, Ellen Scherl, Laura Sahyoun, Dana J Lukin","doi":"10.1093/ibd/izaf044","DOIUrl":"https://doi.org/10.1093/ibd/izaf044","url":null,"abstract":"Background and aims: Ulcerative proctitis (UP) is a limited form of ulcerative colitis. While achieving endoscopic healing (EH) in ulcerative colitis improves long-term outcomes, the benefit of EH in UP is uncertain. This study aimed to assess the impact of EH on outcomes in UP.Methods: This single-center retrospective study included adults with UP and ≥2 endoscopies, with active inflammation (Mayo endoscopic score [MES] 1-3) at index. EH was defined as MES 0-1 at follow-up procedure. The relationship of EH to inflammatory bowel disease (IBD)-related outcomes was assessed using univariate analysis and multivariable logistic regression assessed the effect of EH on IBD-related outcomes.Results: Among 200 UP patients, 109 (54.5%) had EH at follow-up endoscopy at median 19 months (interquartile range: 7, 32). EH was associated with fewer IBD-related emergency department (ED) visits (EH: 8.3%, no EH: 21%, P = .01), hospitalizations (5.5% vs 18%), and GI visits (mean: 1.47/year [SD: 1.40], vs 2.96/year [2.52], P < .001). Patients with EH were less likely to have iron deficiency anemia (23% vs 41%, P = .007), Clostridioides difficile (0.9% vs 6.6%, P = .048), or initiate new biologic therapy after relapse (15% vs 33%, P = .034). Patients with EH had a greater time to clinical relapse (21 [24] vs 9 months [14]; P = .006) and lower odds of an IBD-related ED visit (OR: 0.32, 95% CI: 0.13, 0.73) or hospitalization (0.26 [0.09, 0.67]). Baseline presence of a cecal patch did not impact outcomes.Conclusions: UP patients with EH had less IBD-related healthcare utilization, fewer IBD-related complications, and were less likely to escalate therapy after relapse than patients without EH. Using a treatment target of EH may therefore be desirable in UP.","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Enhancing Surgical Decision-Making in PSC-IBD: A Call for Comprehensive Long-Term Outcomes and Standardized Follow-Up Protocols.

IF 4.5 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-03-26 DOI: 10.1093/ibd/izaf058

Guilin Bai, Yuanzhe Li, Yuexia Zhang

引用次数: 0

Stromal Cell Subsets Show Model-Dependent Changes in Experimental Colitis and Affect Epithelial Tissue Repair and Immune Cell Activation.

IF 4.5 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-03-18 DOI: 10.1093/ibd/izae255

Zhou Zhou, Jie Su, Bram W van Os, Leonie G Plug, Eveline S M de Jonge-Muller, Lei Brands, Stef G T Janson, Lydia M van de Beek, Andrea E van der Meulen-de Jong, Lukas J A C Hawinkels, Marieke C Barnhoorn

{"title":"Stromal Cell Subsets Show Model-Dependent Changes in Experimental Colitis and Affect Epithelial Tissue Repair and Immune Cell Activation.","authors":"Zhou Zhou, Jie Su, Bram W van Os, Leonie G Plug, Eveline S M de Jonge-Muller, Lei Brands, Stef G T Janson, Lydia M van de Beek, Andrea E van der Meulen-de Jong, Lukas J A C Hawinkels, Marieke C Barnhoorn","doi":"10.1093/ibd/izae255","DOIUrl":"https://doi.org/10.1093/ibd/izae255","url":null,"abstract":"Background: Previous work on inflammatory bowel disease (IBD) revealed changes in the abundance of colonic stromal subsets during intestinal inflammation. However, it is currently unknown whether these stromal cell subset changes are also reflected in different IBD mouse models and how commonly used IBD therapies affect stromal cell subset composition.Methods: Stromal subset markers CD55, C-X-C motif chemokine 12 (CXCL12), podoplanin (PDPN), CD90, and CD73 were analyzed by flow cytometry in 3 mouse models for IBD, namely interleukin (IL)-10 knockout (KO), dextran sulfate sodium-induced, and T-cell transfer model for colitis. Next, the effects of IBD therapies on the stromal subset composition were studied. In vitro experiments were performed to study the interaction between stromal cell subsets and epithelial/immune cells.Results: The colitis-induced changes in the abundance of stromal cell subsets differed considerably between the 3 colitis mouse models. Interestingly, treatment with IBD medication affected specific stromal subsets in a therapy and model-specific manner. In vitro experiments showed that specific stromal subsets affected epithelial wound healing and/or T-cell activation.Conclusions: The relative abundance changes of stromal cell subsets during experimental colitis differ between 3 established colitis models. Treatment with IBD therapies influences stromal subset abundance, indicating their importance in IBD pathogenesis, possibly through affecting epithelial migration, and T-cell activation.","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143657180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk Factors for Contraceptive Failure and Unintended Pregnancy Among Women With Inflammatory Bowel Disease.

IF 4.5 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-03-14 DOI: 10.1093/ibd/izaf046

Erica J Brenner, Xian Zhang, Uma Mahadevan, Amy G Bryant, Michael D Kappelman, Millie D Long

引用次数: 0